Complement System and Potential Therapeutics in Age-Related Macular Degeneration.
Young Gun ParkYong Soo ParkIn-Beom KimPublished in: International journal of molecular sciences (2021)
Age-related macular degeneration (AMD) is a complex multifactorial disease characterized in its late form by neovascularization (wet type) or geographic atrophy of the retinal pigment epithelium cell layer (dry type). The complement system is an intrinsic component of innate immunity. There has been growing evidence that the complement system plays an integral role in maintaining immune surveillance and homeostasis in AMD. Based on the association between the genotypes of complement variants and AMD occurrence and the presence of complement in drusen from AMD patients, the complement system has become a therapeutic target for AMD. However, the mechanism of complement disease propagation in AMD has not been fully understood. This concise review focuses on an overall understanding of the role of the complement system in AMD and its ongoing clinical trials. It provides further insights into a strategy for the treatment of AMD targeting the complement system.
Keyphrases
- age related macular degeneration
- clinical trial
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- small molecule
- stem cells
- risk assessment
- prognostic factors
- copy number
- dna methylation
- cancer therapy
- endothelial cells
- bone marrow
- smoking cessation
- vascular endothelial growth factor
- genome wide
- combination therapy